- Report
- February 2023
- 15 Pages
United States
From €2683EUR$2,995USD£2,287GBP
- Report
- February 2023
- 29 Pages
North America
From €3578EUR$3,995USD£3,050GBP
- Report
- February 2023
- 37 Pages
Asia Pacific
From €3578EUR$3,995USD£3,050GBP
- Report
- March 2020
- 49 Pages
Global
€1181EUR$1,318USD£1,006GBP
- Report
- February 2019
United States
From €4026EUR$4,495USD£3,432GBP
- Report
- November 2024
- 84 Pages
Global
From €3500EUR$4,186USD£3,088GBP
- Book
- May 2022
- 1040 Pages
- Book
- September 2023
- 272 Pages
- Book
- September 2023
- 272 Pages
- Book
- May 2022
- 3296 Pages
- Book
- May 2022
- 1040 Pages
- Book
- April 2021
- 448 Pages
- Book
- December 2019
- 560 Pages
- Book
- December 2019
- 560 Pages
- Book
- March 2019
- 480 Pages
- Book
- April 2012
- 1272 Pages
- Book
- November 2008
- 3712 Pages

The Inflammatory Bowel Disease (IBD) market is a subset of the Gastroenterology market, which focuses on the diagnosis and treatment of diseases related to the digestive system. IBD is a chronic condition that affects the digestive tract, causing inflammation and pain. Symptoms of IBD can include abdominal pain, diarrhea, rectal bleeding, and weight loss. Treatment options for IBD include medications, lifestyle changes, and surgery.
IBD is a growing market, with an increasing number of patients seeking treatment. The market is expected to continue to grow as new treatments become available and awareness of the condition increases.
Companies in the IBD market include AbbVie, Allergan, AstraZeneca, Boehringer Ingelheim, Janssen, Merck, Pfizer, and Takeda. Show Less Read more